MicroRNAs in B cell lymphomas: how a complex biology gets more complex

Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Authors

MUSILOVÁ Kateřina MRÁZ Marek

Year of publication 2015
Type Article in Periodical
Magazine / Source Leukemia
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.nature.com/leu/journal/v29/n5/pdf/leu2014351a.pdf
Doi http://dx.doi.org/10.1038/leu.2014.351
Field Oncology and hematology
Keywords microRNAs; BCR; CLL; DLBCL
Attached files
Description MicroRNAs (miRNAs) represent important regulators of gene expression besides transcriptional control. MiRNA regulation can be involved in the cell developmental fate decisions, but can also have more subtle roles in buffering stochastic fluctuations in gene expression. They participate in pathways fundamental to B cell development like B cell receptor (BCR) signalling, B cell migration/adhesion, cell-cell interactions in immune niches, and the production and class-switching of immunoglobulins. MiRNAs influence B cell maturation, generation of pre-, marginal zone, follicular, B1, plasma and memory B cells. In this review, we discuss miRNAs with essential functions in malignant B cell development (such as miR-150, miR-155, miR-21, miR-34a, miR-17-92, miR-15-16). We also put these miRNAs in the context of normal B cell differentiation, since this is intimately connected to neoplastic B cell development. We review miRNAs' role in the most common B cell malignancies, including chronic lymphocytic leukaemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). We focus on miR-contribution to the regulation of important signalling pathways (like NF-KB, PI3K/AKT, TGF-beta), BCR signalling and its modulators (like PTEN, SHIP-1, ZAP-70, GAB1, BTK), anti- and pro-apoptotic proteins (like BCL2, MCL1, TCL1, BIM, p53, SIRT1), and transcription factors (like MYC, MYB, PU.1, FOXP1, BCL6). We also discuss the association of miRNAs expression levels with the patients survival and response to therapy, summarizing their potential use as predictive and prognostic markers. Importantly, the targeting of miRNAs (like use of anti-miR-155 or miR-34a mimic) could provide a novel therapeutic approach as evidenced by tumour regression in xenograft mouse models and initial promising data from clinical trials.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.